This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-26 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Sizing === When used in painting as a sizing, rabbit-skin glue is spread evenly over a canvas that has been placed on a stretcher. When the glue dries, the canvas tightens. The canvas should be left to dry in normal room temperature for at least 12 hours. Under no circumstances should the drying canvas be placed under harsh sunlight or other heat, because the glue will start to crack. Air humidity also affects how tight the canvas will dry. Once the canvas is dry, a second layer of glue should be spread on the canvas and left to dry again. After this, if needed, the canvas can be lightly sanded flat. Then an oil-based primer is applied. A canvas sized with rabbit-skin glue can be made tighter than with other alternatives—such as an acrylic-based gesso—because of the shrinkage. This type of canvas is also valuable because it can be sanded to a flatter texture, which allows the painter to achieve a finer level of detail than can be achieved with a typical acrylic gesso ground. A rabbit-skin glue ground is only appropriate for use under oil paint. Acrylic-based media will flake off a canvas prepared with rabbit-skin glue and are therefore not appropriate. Rabbit-skin glue is considered to be a major cause of cracking in oil paintings by most modern conservators. Because the glue is hygroscopic, it continually absorbs moisture from the atmosphere, causing the glue to swell and shrink as ambient humidity levels change. Over many humidity cycles, this repeated flexing causes the brittle oil paint to crack.
The Samoyed ( SAM-ə-yed or sə-MOY-ed; Russian: самое́дская соба́ка, romanized: samoyédskaya sobáka, or самое́д, samoyéd) is a breed of herding dog with a thick, white, double-layered coat. They are spitz-type dogs which take their name from the Samoyedic peoples. Descending from the Nenets Herding Laika, they are domesticated animals that assist in herding, hunting, protection and sled-pulling.
=== Chemical === Like all actinides, berkelium dissolves in various aqueous inorganic acids, liberating gaseous hydrogen and converting into the berkelium(III) state. This trivalent oxidation state (+3) is the most stable, especially in aqueous solutions, but tetravalent (+4), pentavalent (+5), and possibly divalent (+2) berkelium compounds are also known. The existence of divalent berkelium salts is uncertain and has only been reported in mixed lanthanum(III) chloride-strontium chloride melts. A similar behavior is observed for the lanthanide analogue of berkelium, terbium. Aqueous solutions of Bk3+ ions are green in most acids. The color of Bk4+ ions is yellow in hydrochloric acid and orange-yellow in sulfuric acid. Berkelium does not react rapidly with oxygen at room temperature, possibly due to the formation of a protective oxide layer surface. However, it reacts with molten metals, hydrogen, halogens, chalcogens and pnictogens to form various binary compounds. In 2025 an organometallic compound containing berkelium was synthesized from 0.3 mg of berkelium and named berkelocene.
Abbi Jacobson as Shira Schwooper, the middle of the Schwooper children, and sole daughter of Naomi and Elliot. Born in August 1984, Shira is a lesbian and is married to Kendra, with whom she raises twin boys, Walter and Benjamin, and lives in Oakland, California. Shira is blunt, sardonic, stubborn, and easily holds grudges, but she’s nonetheless still compassionate and loves her family, and has a loving healthy relationship with her wife. As a child, Shira was best friends with Rachel "Baby" Feldstein, and had a romantic relationship with Rachel in high school. However, after catching her making out with a man, Shira discovers Rachel saw her as a fling and feels betrayed, which ends their friendship. Shira cannot conceive children due to primary ovarian insufficiency, so Kendra bears the couple's children. Nicole Byer as Kendra Hooper, a lesbian and Shira's wife, who converts to Judaism as an adult after lying about being Jewish to cover up for a work absence during Rosh Hashanah. Born in 1982, Kendra is more grounded than her wife and loves her in spite of her stubborn tendencies. Kendra works as a senior manager for B.J Banana Fingers, a children's entertainment fast-food chain similar to Chuck E. Cheese. She gained her role due to her being a former workaholic who over-exerted herself—a habit she picked up from her father—after being accepted into a managerial training program when she was a floor manager. Kendra fired an employee who helped her as a child in order to gain a higher position by setting her up, which Kendra will have to live with.
Sources: en.wikipedia.org
More potential nutrients from the grape must (though the bacteria will be competing with the yeast for these) Lower sulfur dioxide and ethanol levels which can otherwise inhibit the LAB Higher fermentation temperatures which are more conducive to LAB growth and an earlier completion of MLF: The optimal temperatures for malolactic fermentation are between 20 and 37 °C (68 and 99 °F), while the process is significantly inhibited at temperatures below 15 °C (59 °F). Wine stored in the barrels in the cellar during the winter following fermentation will often have a very prolonged malolactic fermentation due to the cool cellar temperatures. Early completion of malolactic fermentation means the winemaker can make a postfermentation SO2 earlier to protect the wine from oxidation and spoilage microbes (such as Acetobacter). Since sulfur dioxide can inhibit MLF, delaying LAB inoculation till after alcoholic fermentation may mean a delay in sulfur addition till early spring when cellar temperatures warm up enough to encourage the completion of MLF. Less diacetyl production The disadvantages for early inoculation include:
== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
Lt. Col. J. H. Fuller (18 April 1909 – 1 April 1911) Maj. Gordon Vallancy Drury (1 April 1911 – 28 January 1913) Maj. Gen. Sir Alfred Hamilton Mackenzie Edwards (28 January 1913 – 23 January 1923) Col. Algernon Essex Capell (1 February 1923 – 11 February 1926) Alfred James Tomlinson (12 February 1926 – 12 May 1926; acting) Col. George Stops (13 May 1926 – 14 February 1933) Brig. John Sidney Morris (15 February 1933 – 24 April 1945) Brig. John Ellis "Jack" Ross (24 April 1945 – 6 December 1950) Col. James Appleby (7 December 1950 – 2 June 1954) Col. Arthur Selwyn Hickman (3 June 1954 – 5 November 1955) Col. Harold Jackson (6 November 1955 – 12 March 1958) Basil Gordon Spurling (13 March 1958 – 25 April 1963) Frank Eric Barfoot (26 April 1963 – 2 January 1968) James Spink (3 January 1968 – 26 June 1970) Sydney Frederick Samuel Bristow (27 June 1970 – 6 February 1974) Peter Dennis Wray Richard Sherren (7 February 1974 – 6 February 1978) Peter Kevin Allum (7 February 1978 – 6 February 1982)
Sources: en.wikipedia.org
== Federal Republic of Germany (1949–present) == In 1949, two separate German states were established: the Federal Republic of Germany (known as West Germany) and the German Democratic Republic (known as East Germany). The list below gives the chancellors of West Germany; the government of East Germany was headed by the chairman of the Council of Ministers. In 1990, East Germany was dissolved as it merged with West Germany; Germany was reunified. It retained the name of the Federal Republic of Germany. Political parties: CDU (6) SPD (4)
== S == Sac6 Sla1p Srv2 (CAP) S-adenosyl-L-homocysteine hydrolase, (SAHH) Sla2p Synaptopodin Scinderin (adseverin) Synapsins Scruin Spectrin Severin Spectraplakins SVSII Shot (Short stop) Spire Shroom Smitin (Smooth Musc.Titin) Supervillin SipA Smoothelin Sucrose synthetase SipC Sra-1 Spinophilin Ssk2p Swinholide
=== Mechanism of action === Ivermectin and its related drugs act by interfering with the nerve and muscle functions of helminths and insects. The drug binds to glutamate-gated chloride channels common to invertebrate nerve and muscle cells. The binding pushes the channels open, which increases the flow of chloride ions and hyper-polarizes the cell membranes, paralyzing and killing the invertebrate. Ivermectin is safe for mammals (at the normal therapeutic doses used to cure parasite infections) because mammalian glutamate-gated chloride channels only occur in the brain and spinal cord: the causative avermectins usually do not cross the blood–brain barrier, and are unlikely to bind to other mammalian ligand-gated channels.
In August 1935, Albert Rowe, secretary of the Tizard Committee, coined the term "Radio Direction and Finding" (RDF), deliberately choosing a name that could be confused with "Radio Direction Finding", a term already in widespread use. In a 9 September 1935 memo, Watson-Watt outlined the progress to date. At that time the range was about 40 mi (64 km), so Watson-Watt suggested building a complete network of stations 20 mi (32 km) apart along the entire east coast. Since the transmitters and receivers were separate, to save development costs he suggested placing a transmitter at every other station. The transmitter signal could be used by a receiver at that site as well as the ones on each side of it. This was quickly rendered moot by the rapid increases in range. When the Committee next visited the site in October, the range was up to 80 mi (130 km), and Wilkins was working on a method for height finding using multiple antennas. In spite of its ad hoc nature and short development time of less than six months, the Orfordness system had already become a useful and practical system. In comparison, the acoustic mirror systems that had been in development for a decade were still limited to only 5 mi (8.0 km) range under most conditions, and were very difficult to use in practice. Work on mirror systems ended, and on 19 December 1935, a £60,000 contract for five RDF stations along the south-east coast was sent out, to be operational by August 1936. The only person not convinced of the utility of RDF was Lindemann.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.